Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM
NCT05914662
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
42
Enrollment
OTHER
Sponsor class
Conditions
Waldenstrom Macroglobulinemia
Interventions
DRUG:
Zanubrutinib, Bendamustine and Rituximab
Sponsor
Institute of Hematology & Blood Diseases Hospital, China